{"url_path":"/sec/aim/8-k/2026-06-10/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-10","source_url":"https://www.sec.gov/Archives/edgar/data/946644/0001493152-26-028129-index.html","accession_number":"0001493152-26-028129","cik":"0000946644","ticker":"AIM","issuer_name":"AIM ImmunoTech Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/946644/0001493152-26-028129-index.html","primary_entity_key":"0000946644","primary_entity_name":"AIM ImmunoTech Inc."},"word_count":85,"has_tables":true,"body_markdown":"**Item\n9.01**\n**Financial\nStatements and Exhibits.**\n\n \n\n(d)\nExhibits\n\n \n\n**Exhibit\nNo.**\n \n**Description**\n\n3.1\n \n[Amendment to the Amended and Restated Bylaws, effective as of June 9, 2026.](ex3-1.htm)\n\n104\n \nCover\nPage Interactive Data File (embedded within the Inline XBRL document).\n\n \n\n \n\n \n\n** **\n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\nDate:\nJune 10, 2026\n**AIM\nImmunoTech Inc.**\n\n \n \n\n \n*/s/\nThomas K. Equels*\n\n \nThomas\nK. Equels\n\n \nChief\nExecutive Officer\n\n \n\n \n\n \n\n****"}